Levomilnacipran
Molecular structure of levomilnacipran | |
3D representation of levomilnacipran | |
| Clinical data | |
|---|---|
| Trade names | Fetzima |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a613048 |
| License data | |
| Routes of administration | By mouth |
| Drug class | Serotonin–norepinephrine reuptake inhibitor (SNRI) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 92% |
| Protein binding | 22% |
| Metabolism | Liver (primarily by CYP3A4) |
| Elimination half-life | 12 hours |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H22N2O |
| Molar mass | 246.354 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Levomilnacipran, sold under the brand name Fetzima, is an antidepressant medication used for the treatment of major depressive disorder in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor.
Levomilnacipran was approved for medical use in the United States in July 2013.